GlassScriptPhysician profile
Khaled M Selim
NPI 1174688071
$56,739.63
in general payments reported to CMS, 2019-2025
12 companies · $9,209 in 2025
The $9,209 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $8,706 · 2021: $1,242 · 2022: $356 · 2023: $146 · 2024: $13K · 2025: $9,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $2,200 · Food and Beverage: $2,002 · Honoraria: $1,080 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,274.00 |
| Travel and Lodging | $2,200.00 |
| Food and Beverage | $2,002.15 |
| Honoraria | $1,080.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $20,491.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $18,679.67 | 2019-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $14,753.48 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $1,167.87 | 2024-2025 | Iqirvo |
| Abbvie INC. | $935.34 | 2019-2025 | Mavyret |
| Mallinckrodt Hospital Products INC. | $288.80 | 2023-2025 | Terlivaz |
| Novo Nordisk INC | $133.53 | 2021-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $98.20 | 2019 | |
| Erbe USA INC | $79.14 | 2019 | |
| Glaxosmithkline, LLC. | $50.15 | 2024 | |
| Histosonics, INC. | $46.47 | 2024 | |
| Shionogi INC | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Selim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.